Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AKBA Akebia Therapeutics	$3.86 -0.1%	$3.42	$1.07 ▼ $4.08	$1.01B	0.88	3.15 million shs	34,162 shs
AMRN Amarin	$15.98 +1.0%	$13.57	$7.08 ▼ $17.49	$330.84M	0.82	83,561 shs	542 shs
CVAC CureVac	$5.41 +0.3%	$4.85	$2.37 ▼ $5.72	$1.21B	2.53	776,051 shs	602 shs
ELVN Enliven Therapeutics	$22.80 -2.3%	$20.10	$13.30 ▼ $30.03	$1.13B	0.83	305,842 shs	349,364 shs

The Best High-Yield Dividend Stocks for 2025

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AKBA Akebia Therapeutics	0.00%	-1.78%	+4.89%	+86.47%	+185.93%
AMRN Amarin	0.00%	-6.56%	+26.16%	+65.65%	+0.79%
CVAC CureVac	0.00%	-1.28%	-0.92%	+67.91%	+46.87%
ELVN Enliven Therapeutics	0.00%	+0.94%	+6.38%	+39.70%	+2.95%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AKBA Akebia Therapeutics	3.7394 of 5 stars	3.6	1.0	4.0	2.3	0.8	0.6
AMRN Amarin	0.316 of 5 stars	0.5	3.0	0.0	1.9	0.0	0.6
CVAC CureVac	4.0718 of 5 stars	4.1	5.0	4.9	0.0	0.0	1.3
ELVN Enliven Therapeutics	2.9037 of 5 stars	3.5	2.0	0.0	2.6	4.2	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AKBA Akebia Therapeutics	3.20	Buy	$6.75	75.10% Upside
AMRN Amarin	1.00	Sell	$12.00	-24.88% Downside
CVAC CureVac	2.20	Hold	$6.83	26.43% Upside
ELVN Enliven Therapeutics	3.00	Buy	$41.20	80.70% Upside

Current Analyst Ratings Breakdown

Latest AMRN, AKBA, CVAC, and ELVN Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/2/2025	ELVN Enliven Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$40.00 ➝ $48.00
6/26/2025	CVAC CureVac	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Neutral	$12.00 ➝ $5.50
6/25/2025	AMRN Amarin	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Sell ➝ Sell	$7.00 ➝ $12.00
6/16/2025	ELVN Enliven Therapeutics	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$40.00 ➝ $52.00
6/16/2025	ELVN Enliven Therapeutics	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$37.00
6/13/2025	CVAC CureVac	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Hold	$7.00 ➝ $5.00
6/12/2025	CVAC CureVac	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Market Perform
6/12/2025	CVAC CureVac	Citizens Jmp Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
6/4/2025	AKBA Akebia Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$8.00
5/28/2025	CVAC CureVac	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$10.00
5/16/2025	ELVN Enliven Therapeutics	Jones Trading Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$36.00 ➝ $27.00

(Data available from 7/21/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AKBA Akebia Therapeutics	$160.18M	6.32	N/A	N/A	($0.23) per share	-16.76
AMRN Amarin	$228.61M	1.45	N/A	N/A	$23.62 per share	0.68
CVAC CureVac	$579.18M	2.09	$0.88 per share	6.17	$3.36 per share	1.61
ELVN Enliven Therapeutics	N/A	N/A	N/A	N/A	$6.34 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AKBA Akebia Therapeutics	-$69.41M	-$0.21	N/A	N/A	N/A	-24.51%	N/A	-18.92%	8/6/2025 (Estimated)
AMRN Amarin	-$82.18M	-$3.64	N/A	N/A	N/A	-41.07%	-17.21%	-12.16%	7/30/2025 (Estimated)
CVAC CureVac	$175.50M	$0.92	5.88	N/A	N/A	35.44%	30.89%	25.54%	8/13/2025 (Estimated)
ELVN Enliven Therapeutics	-$89.02M	-$1.92	N/A	N/A	N/A	N/A	-31.84%	-30.09%	8/12/2025 (Estimated)

Latest AMRN, AKBA, CVAC, and ELVN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	AKBA Akebia Therapeutics	-$0.02	N/A	N/A	N/A	N/A	N/A
8/13/2025	Q2 2025	CVAC CureVac	-$0.15	N/A	N/A	N/A	$4.27 million	N/A
8/12/2025	Q2 2025	ELVN Enliven Therapeutics	-$0.54	N/A	N/A	N/A	N/A	N/A
7/30/2025	Q2 2025	AMRN Amarin	-$0.60	N/A	N/A	N/A	$45.45 million	N/A
5/22/2025	Q1 2025	CVAC CureVac	-$0.16	-$0.24	-$0.08	-$0.24	$4.27 million	$0.94 million
5/14/2025	Q1 2025	ELVN Enliven Therapeutics	-$0.51	-$0.57	-$0.06	-$0.57	N/A	N/A
5/8/2025	Q1 2025	AKBA Akebia Therapeutics	-$0.03	$0.03	+$0.06	$0.03	$44.88 million	$57.34 million
5/7/2025	Q1 2025	AMRN Amarin	-$0.06	-$0.04	+$0.02	-$0.04	$50.75 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AKBA Akebia Therapeutics	N/A	N/A	N/A	N/A	N/A
AMRN Amarin	N/A	N/A	N/A	N/A	N/A
CVAC CureVac	N/A	N/A	N/A	N/A	N/A
ELVN Enliven Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AKBA Akebia Therapeutics	1.89	2.23	2.02
AMRN Amarin	N/A	3.53	2.55
CVAC CureVac	0.05	7.65	7.64
ELVN Enliven Therapeutics	N/A	21.07	21.06

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AKBA Akebia Therapeutics	33.92%
AMRN Amarin	22.25%
CVAC CureVac	17.26%
ELVN Enliven Therapeutics	95.08%

Insider Ownership

Company	Insider Ownership
AKBA Akebia Therapeutics	3.00%
AMRN Amarin	1.96%
CVAC CureVac	N/A
ELVN Enliven Therapeutics	25.90%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AKBA Akebia Therapeutics	430	262.64 million	254.76 million	Optionable
AMRN Amarin	360	20.71 million	20.30 million	Optionable
CVAC CureVac	880	224.34 million	N/A	Optionable
ELVN Enliven Therapeutics	50	49.07 million	36.36 million	Optionable

AMRN, AKBA, CVAC, and ELVN Headlines

Recent News About These Companies

Enliven Therapeutics (NASDAQ:ELVN) Stock Price Up 8.4% - Here's What Happened

July 18 at 9:26 PM | marketbeat.com

Enliven Therapeutics’ Promising Phase 1a/1b Study on ELVN-002 in HER2+ Cancers

July 18 at 12:08 PM | tipranks.com

Can Enliven Therapeutics, Inc. (ELVN) Climb 75.66% to Reach the Level Wall Street Analysts Expect?

July 18 at 10:56 AM | zacks.com

Enliven Therapeutics (NASDAQ:ELVN) Shares Down 5.7% - Here's What Happened

July 15, 2025 | marketbeat.com

Enliven Therapeutics, Inc. (NASDAQ:ELVN) CFO Sells $22,660.00 in Stock

July 15, 2025 | insidertrades.com

Benjamin Hohl Sells 1,000 Shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN) Stock

July 14, 2025 | marketbeat.com

Enliven Therapeutics Breaks Above 200-Day Moving Average - Nasdaq

July 12, 2025 | nasdaq.com

Enliven Therapeutics, Inc. (NASDAQ:ELVN) Receives Average Rating of "Buy" from Brokerages

July 11, 2025 | americanbankingnews.com

Enliven Therapeutics, Inc. (NASDAQ:ELVN) Receives Average Recommendation of "Buy" from Brokerages

July 11, 2025 | marketbeat.com

Enliven Therapeutics, Inc. (NASDAQ:ELVN) COO Anish Patel Sells 6,667 Shares

July 9, 2025 | marketbeat.com

Enliven Therapeutics (NASDAQ:ELVN) Trading 5.4% Higher - What's Next?

July 9, 2025 | marketbeat.com

Q2 EPS Forecast for Enliven Therapeutics Boosted by Analyst

July 4, 2025 | marketbeat.com

Enliven Therapeutics (NASDAQ:ELVN) Shares Up 7.9% Following Analyst Upgrade

July 2, 2025 | marketbeat.com

Enliven Therapeutics (NASDAQ:ELVN) Stock Price Expected to Rise, HC Wainwright Analyst Says

July 2, 2025 | marketbeat.com

Benjamin Hohl Sells 3,250 Shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN) Stock

July 2, 2025 | insidertrades.com

Enliven Therapeutics, Inc. (NASDAQ:ELVN) CFO Benjamin Hohl Sells 3,250 Shares

July 1, 2025 | marketbeat.com

Enliven Therapeutics’ Promising CML Study: A Potential Game-Changer?

June 30, 2025 | tipranks.com

Insider Selling: Enliven Therapeutics, Inc. (NASDAQ:ELVN) Insider Sells 12,500 Shares of Stock

June 24, 2025 | marketbeat.com

Enliven Short Interest Falls To 14-Month Low After Leukemia Trial Data, Goldman Initiates With ‘Buy’

June 23, 2025 | msn.com

Goldman Sachs initiates Enliven Therapeutics stock with Buy rating

June 17, 2025 | investing.com

Enliven grosses $230M from stock sale

June 17, 2025 | bizwest.comB

New MarketBeat Followers Over Time

Media Sentiment Over Time

AMRN, AKBA, CVAC, and ELVN Company Descriptions

Akebia Therapeutics NASDAQ:AKBA

$3.86 -0.01 (-0.13%)

As of 09:46 AM Eastern

Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent patients. It offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD on dialysis; and the treatment of iron deficiency anemia in adult patients with CKD not on dialysis. The company's product pipeline includes AKB-9090, a drug targeting critical-care indications; and AKB-10108, a drug targeting conditions related to premature birth. It has collaboration agreements with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of hypoxia-inducible factor prolyl hydroxylase targeted compounds worldwide. Akebia Therapeutics, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

Amarin NASDAQ:AMRN

$15.98 +0.16 (+0.98%)

As of 09:46 AM Eastern

Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, European countries, Canada, Lebanon, and the United Arab Emirates. The company offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. It sells its products principally to wholesalers and specialty pharmacy providers. The company has a collaboration with Mochida Pharmaceutical Co., Ltd. to develop and commercialize drug products and indications based on the active pharmaceutical ingredient in Vascepa. The company was formerly known as Ethical Holdings plc and changed its name to Amarin Corporation plc in 1999. Amarin Corporation plc was incorporated in 1989 and is headquartered in Dublin, Ireland.

CureVac NASDAQ:CVAC

$5.40 +0.02 (+0.28%)

As of 09:47 AM Eastern

CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202 which is in Phase 1 clinical trial for the treatment of rabies; and CVSQIV to treat multivalent seasonal influenza; Flu SV mRNA fot treating nucleotides, single antigen seasonal influenza. The company develops CV8102, which is in Phase 1 clinical trial for treating melanoma and adenoidcystic carcinoma, as well as squamous cell cancer of skin, head, and neck; and CVGBM for treating cancer. CureVac N.V. was founded in 2000 and is headquartered in Tübingen, Germany.

Enliven Therapeutics NASDAQ:ELVN

$22.80 -0.54 (-2.31%)

As of 09:46 AM Eastern

Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations. The company is headquartered in Boulder, Colorado.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time